In the current study, we extended our studies of the vaccine potential of rT-Nm-MIP by (i) examining the antigenicity of independent batches of experimental vaccines against meningococci and gonococci, (ii) using HC/HS-SBA assays to quantify bactericidal activity against meningococci and gonococci expressing different MIP Type proteins and (iii) attempting to engineer the MenB OM to express truncated MIP. This evidence concerns the gene MIP and ocular melanoma.